BNR (Burning Rock Biotech) ROCE % : -20.98% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Burning Rock Biotech's annualized ROCE % for the quarter that ended in Sep. 2024 was -20.98%.

Burning Rock Biotech ROCE % Historical Data

The historical data trend for Burning Rock Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech ROCE % Chart

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-41.45

-26.59

-37.25

-60.10

-65.75

Burning Rock Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-76.58	-72.82	-66.54	-59.37	-20.98

Burning Rock Biotech ROCE % Calculation

Burning Rock Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-91.216	/	( ( (227.702 - 59.017)	+	(145.654 - 36.885) )	/ 2 )
	=	-91.216	/	( (168.685	+	108.769)	/ 2 )
	=	-91.216	/	138.727
	=	-65.75 %

Burning Rock Biotech's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-21.816	/	( ( (141.065 - 35.789)	+	(139.175 - 36.529) )	/ 2 )
	=	-21.816	/	( ( 105.276	+	102.646 )	/ 2 )
	=	-21.816	/	103.961
	=	-20.98 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Burning Rock Biotech (NAS:BNR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Burning Rock Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

6BU0:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.